Regentis Biomaterials

Board of Directors

Dr. Ehud Geller, Chairman

Dr. Ehud Geller, Chairman - Founder & Managing Partner, Medica Venture Partners

Dr. Ehud Geller has been active in the health care/biopharma and life science industries for over 30 years. The former president and CEO of Interpharm Laboratories, Ltd., he presided over the growth of this company from the seed stage to $18 million in revenues. Prior to that, Dr. Geller, was the president of the Pharmaceutical Division of Teva and Executive VP of the Teva Group, Israel´s largest pharmaceutical company. At Teva he led the merger of the pharmaceutical business involved in the acquisition of Ikapharm Ltd., and the strategy of Teva´s entry into the U.S. market. Earlier, Dr. Geller conducted pharmaceutical research at Wyeth Laboratories in the U.S. Dr. Geller has a B.Sc. degree in chemical engineering, an MBA from Columbia University, and a Ph.D. degree in pharma/chemical engineering from Drexel Institute. He serves as founder and director of biotech and device health care companies.

Mr. Jeff Dykan

Mr. Jeff Dykan - Managing Partner, SCP Vitalife

Mr. Dykan began his career with Andersen Consulting in New York and has over 25 years experience in finance, business development and general management in global growth companies and startups. He has had a lead role in managing investments of Vitalife, including arranging financings. Prior to joining Vitalife, he was Chairman and CEO of BitBand, an IP broadband start up, and held several senior financial positions, including as CFO at VocalTec Communications, as Director of Regional Finance for Applied Materials in Israel and VP Finance at Opal. Mr. Dykan is Chairman of Trig Medical and serves on board of directors of Deep Breeze, Quantomix, BetaO2, Genegrafts, Niti Surgical Solutions and the Technion Incubator. He has a B.S. in accounting and management from New York University and an MBA in computer applications also from New York University. Mr. Dykan is also licensed in New York State as a certified public accountant.

Eli Hazum, Ph.D.

Eli Hazum, Ph.D. - Partner & Chief Scientist, Medica Venture Partners

Dr. Eli Hazum received his Ph.D. degree from the Weizmann Institute of Science in 1978 in the area of hormone mechanisms. The author of more than 100 scientific publications in various areas of drug development, he started his professional career as a professor at the Weizmann Institute. Later, he spent 5 years at Glaxo Inc., in North Carolina as the department head of Receptor Research and Metabolic Diseases. Returning to Israel in 1992, Dr. Hazum served in various executive research positions at Biotechnology General Corp. and as V.P. of R&D at Peptor Ltd., before joining Medica Venture Partners as Chief Scientific Officer.

Ian Freelance

Ian Freelance - Investment Manager, DSM Venturing B.V.

Mr Freelance joined the DSM Corporate Venturing unit in 2007.  Prior to that, he held various business development and general management positions within the pharmaceutical industry over a period of 15 years.  In his last position, he was leading an internal DSM start-up, producing early phase clinical material for both large pharma and biotech start-ups in the U.S. and Europe.

He serves on the boards of Novomer, SkySails, BioProcess Control, CellMade in addition to a number of observer positions.

He holds an MSc in Chemistry from Sheffield University in the U.K.

Mr. Junmin Wang

Mr. Junmin Wang - President, CEO, Founder of Haisco Pharmaceutical

•Bachelor, Shenyang Pharmaceutical University.
•EMBA, Cheung Kong Graduate School of Business
•DBA, Cheung Kong Graduate School of Business
•EMBA, TsinghuaUniversity
•CEO class, Shanghai Advanced Institute of Finance (SAIF)

With almost 20 years industrial working practice, Mr. Wang has rich experience in pharmaceutical enterprise operation and management, sharp business market sense and a deeper understanding about the pharmaceutical research, development and sales in both domestic and oversea.

Keith C. Valentine, Independent Director

Keith C. Valentine, Independent Director - President, Chief Executive Officer & Director of SeaSpine

Keith C. Valentine serves as President, Chief Executive Officer and as a director of SeaSpine. Prior to joining SeaSpine, Mr. Valentine served as President and Chief Operating Officer of NuVasive, Inc., from 2007 to 2015 and as President from 2004 to 2007, prior to which he served in various senior executive roles in Marketing, Development and Operations since joining the company in 2001. Previously, Mr. Valentine was Vice President of Marketing at ORATEC Interventions, Inc., which was acquired by Smith & Nephew PLC, and spent eight years in various roles with Medtronic Sofamor Danek including Vice President of Marketing for the Thoracolumbar Division and Group Director for the BMP Biologics program, the Interbody Sales Development Effort, and International Sales and Marketing. Mr. Valentine received a B.B.A. in Management and Biomedical Sciences from Western Michigan University.